Post-marketing safety of bimekizumab in psoriasis patients: pharmacovigilance data from FDA adverse event reporting system
收藏Mendeley Data2026-04-18 收录
官方服务：
资源简介：
The set of supplementary materials support findings of the study "Post-marketing safety of bimekizumab in psoriasis patients: pharmacovigilance data from FDA adverse event reporting system" which has been accepted in the International Journal of Dermatology. The dataset includes Supplementary Methods and 2 Supplementary Tables.
创建时间：
2025-09-10
